As the coronavirus has spread across our country, our personal and professional lives have been impacted in unimaginable ways. Yet, amidst this, we are beginning to see glimmers of hope and optimism both in our country and in many other parts of the world. With these changes, comes hope.
For many of us, with practices closed, the last thing you are likely thinking about is investing in your practice. For others, you may be looking at this time as a chance to reassess and reinvest as opportunities abound. History has shown that the right investments even at the most challenging of times, can often help with a faster recovery and be an amazing ROI.
To help you and your practice prepare for a healthy restart, we are proudly offering unprecedented offers during these unprecedented times. With offers of not only low pricing and big discounts, low down payments and low monthly payments, but possibly even deferred payments until 2021 (OAC)! We have a variety of compelling offers for those who may be considering an investment in energy-based devices to support a healthy restart!
As each of you will be making your own decisions on how and when your practices are ready to re-start, we want to assure you that we are ready and here for you, when you are. We're in this together and together we got this!
"THIS TOO SHALL PASS"
Find some helpful links from our partners below:
Recorded webinar will be added when available!
Healeon Medical is committed to advancing science and therapeutics by providing support and resources to learn more about the various technologies and therapies that are resultant from their products. Healeon Medical's participation in sponsoring studies to help develop promising treatments and improve outcomes in a variety of applications is a large part of being a regenerative resource and one in which we take great pride in.
CURRENT STUDIES: COVID-19 Treatment For Lung Complications
Healeon's safe and reliable CENTRIcyte 1000 system for isolating autologous stem cells is currently involved in several studies where intravenous administration of stem cells are administered to investigate treatment outcomes for COVID-19 patients, including one from our Chief Medical Officer, Dr. Robert Alexander, for lung complications associated with COVID-19.